Evidence map›Paper›PMID 31925976›Full record

ArticleCancer science2020

High infiltration of mast cells is associated with improved response to adjuvant chemotherapy in gallbladder cancer.

Xiaobo Bo, Jie Wang, Changcheng Wang, Lingxi Nan, Zhihui Gao, Yanlei Xin, Min Li, Sheng Shen, Han Liu, Xiaoling Ni and 5 more

Open access · goldAbstract read
In one paragraph

Article in Cancer science, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.6field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 2 institutions in 1 country.

Xiaobo BoDepartment of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.
Jie WangDepartment of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.
Changcheng WangDepartment of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.
Lingxi NanDepartment of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.
Zhihui GaoDepartment of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.
Yanlei XinDepartment of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.
Min LiDepartment of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.
Sheng ShenDepartment of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.
Han LiuDepartment of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.
Xiaoling NiDepartment of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.
Tao SuoDepartment of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.
Dexiang ZhangGeneral Surgery Department, Zhongshan-Xuhui Hospital Affiliated to Fudan University, Shanghai, China.
Pinxiang LuGeneral Surgery Department, Zhongshan-Xuhui Hospital Affiliated to Fudan University, Shanghai, China.
Yueqi WangDepartment of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.ORCID https://orcid.org/0000-0002-0374-1045
Houbao LiuDepartment of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.ORCID https://orcid.org/0000-0003-0608-6522
Sun Yat-sen University · CNFudan University · CN

Funding

Clinical Study of Zhongshan Hospital 2018ZSLC24Foundation of Shanghai Science and Technology Committee 16411952000JianFeng project of XuHui Provincial Commission of Health and Family Planning SHXH201703National Natural Science Foundation of China 81872352Shanghai Medical Discipline of Key Programs for General Surgery 2017ZZ02007
6 · The paper itself

Abstract

Recent studies have reported that tumor-infiltrating mast cells (TIM) play an important role in tumor regression, but the effect of TIM in gallbladder cancer (GBC) remains unclear. The present study aims to investigate the prognostic value of TIM in GBC patients and its responsiveness to gemcitabine-based adjuvant chemotherapy (ACT). A total of 298 GBC patients from Zhongshan Hospital were recruited for this study. TIM infiltration was measured by immunohistochemical staining. Accumulation of TIM is significantly associated with prolonged overall survival in GBC patients. The benefit from gemcitabine-based ACT was superior among patients with high infiltration of TIM with GBC. Multivariate analysis identified TIM infiltration as an independent prognostic factor for overall survival. A heatmap showed that TIM-activated gene signatures were positively correlated with CD8+ T cells' gene signatures. Gene set enrichment analysis (GSEA) suggested that TIM was related to multiple T cell-related processes and signaling pathways, including the interferon gamma signaling pathway and the leukocyte migration signaling pathway. It was confirmed that CD8+ T cell infiltration was positively correlated with high TIM infiltration in tissue microarray (TMA), suggesting that TIM infiltration was linked to the immune surveillance in GBC. TIM can be used as an independent prognostic factor and a predictor of therapeutic response of gemcitabine-based ACT in GBC patients, which may mediate immune surveillance by recruiting and activating CD8+ T cells in GBC.

Indexed as

Antimetabolites, AntineoplasticCD8-Positive T-LymphocytesChemotherapy, AdjuvantDeoxycytidineFemaleGallbladder NeoplasmsGemcitabineHumansInterferon-gammaLymphocytes, Tumor-InfiltratingMaleMast CellsMiddle AgedPrognosisSignal TransductionAntimetabolites, AntineoplasticDeoxycytidineGemcitabineInterferon-gammaadjuvant chemotherapygallbladder cancerprognosistumor immunetumor-infiltrating mast cells

Identifiers

PMID31925976
PMCPMC7060478
OpenAlexW3000208880

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.